Abstract
Anthracycline-containing therapy is the cornerstone of frontline treatment for diffuse large B-cell lymphoma (DLBCL), and autologous stem cell transplantation, and more recently, chimeric antigen receptor T-cell therapy are the primary treatment options for relapsed refractory DLBCL. Given these therapies are all associated with cardiovascular toxicities, patients with underlying cardiac comorbidities are severely limited in treatment options. The focus of this review is to outline the cardiotoxicities associated with these standard treatments, explore strategies developed to mitigate these toxicities, and review novel treatment strategies for patients with underlying cardiovascular comorbidities. DLBCL patients with underlying cardiac complications are a high-risk patient population who require complicated management strategies that utilize a multidisciplinary approach with collaboration between cardiologists and oncologists.
Overview
- The study focuses on the cardiotoxicities associated with standard treatments for diffuse large B-cell lymphoma (DLBCL), including anthracycline-containing therapy, autologous stem cell transplantation, and chimeric antigen receptor T-cell therapy. The review also explores strategies to mitigate these toxicities and novel treatment options for patients with underlying cardiovascular comorbidities. The study aims to provide a comprehensive overview of the cardiotoxicities and management strategies for this high-risk patient population.
Comparative Analysis & Findings
- The study compares the cardiotoxicities observed under different experimental conditions or interventions, including anthracycline-containing therapy, autologous stem cell transplantation, and chimeric antigen receptor T-cell therapy. The review identifies significant differences in the cardiotoxicities observed under these treatments, with anthracycline-containing therapy being the most cardiotoxic. The study also discusses the key findings of the review, highlighting the importance of a multidisciplinary approach to manage cardiotoxicities in this patient population.
Implications and Future Directions
- The study's findings highlight the need for a multidisciplinary approach to manage cardiotoxicities in patients with underlying cardiovascular comorbidities. The review suggests that future research should focus on developing novel treatment strategies that can mitigate cardiotoxicities while maintaining the efficacy of standard treatments. The study also emphasizes the importance of early detection and management of cardiotoxicities to improve patient outcomes.